Patents by Inventor Siamak Tabibzadeh
Siamak Tabibzadeh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20160213008Abstract: Food consumed by humans may not have innate antimicrobial activity and for this reason, it requires preservatives to prevent microbial spoilage and to extend food shelf life. Disclosed herein is a method for capture, and slow, and sustained release of food derived preservative and anti-microbials from a matrix with ultrasonically derived micro-droplets. The growth of microbes on food and other perishable or non-perishable items is prevented and food freshness is extended by keeping them within an environment where preservative is slowly released.Type: ApplicationFiled: January 26, 2016Publication date: July 28, 2016Inventor: Siamak TABIBZADEH
-
Publication number: 20140342065Abstract: Food spoilage leads to food wastage, human morbidity and mortality. This food preservation takes advantage of use of Hydrogen Sulfide without or with Hydrogen or Helium into an environment where food is stored. The method delays food ripening, food spoilage, food decay and is safe, and preserves the natural characteristics of food, including color, flavor, aroma and texture. Hydrogen Sulfide treatment maintains higher activities of catalase, guaiacol peroxidase, ascorbate peroxidase, glutathione reductase and lower activities of lipoxygenase relative to un-treated controls. Hydrogen Sulfide also reduces malondialdehyde, Hydrogen peroxide, and superoxide anion to levels below those in control fruits during storage. Hydrogen and Helium are administered as gas and Hydrogen Sulfide is administered as a gas, liquid, or a Hydrogen Sulfide donor, within a closed environment or by providing Hydrogen Sulfide within the item.Type: ApplicationFiled: January 7, 2013Publication date: November 20, 2014Inventor: Siamak TABIBZADEH
-
Publication number: 20120149017Abstract: The subject invention pertains to methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometrial tissue. Methods for diagnosing endometrial receptivity and bleeding function by screening a biological sample such as an endometrial tissue sample, or bodily fluid for the presence of ebaf. A contraceptive compound containing an effective amount of ebaf and a pharmaceutically acceptable carrier. A diagnostic kit for timing contraception containing reagents for screening a sample for the presence of ebaf. A method of treating endometrial irregularities by down-regulating the expression of ebaf.Type: ApplicationFiled: January 5, 2012Publication date: June 14, 2012Applicant: University of South FloridaInventors: SIAMAK TABIBZADEH, Ravi Kothapalli
-
Patent number: 8106001Abstract: The subject invention pertains to methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometrial tissue. Methods for diagnosing endometrial receptivity and bleeding function by screening a biological sample such as an endometrial tissue sample, or bodily fluid for the presence of ebaf. A contraceptive compound containing an effective amount of ebaf and a pharmaceutically acceptable carrier. A diagnostic kit for timing contraception containing reagents for screening a sample for the presence of ebaf. A method of treating endometrial irregularities by down-regulating the expression of ebaf.Type: GrantFiled: April 27, 2007Date of Patent: January 31, 2012Assignee: University of South FloridaInventors: Siamak Tabibzadeh, Ravi Kothapalli
-
Publication number: 20100292451Abstract: A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.Type: ApplicationFiled: November 16, 2009Publication date: November 18, 2010Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Siamak Tabibzadeh, Ravi Kothapalli
-
Patent number: 7705131Abstract: A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.Type: GrantFiled: January 17, 2007Date of Patent: April 27, 2010Assignee: University of South FloridaInventors: Siamak Tabibzadeh, Ravi Kothapalli
-
Publication number: 20080200379Abstract: The subject invention pertains to methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometrial tissue. Methods for diagnosing endometrial receptivity and bleeding function by screening a biological sample such as an endometrial tissue sample, or bodily fluid for the presence of ebaf. A contraceptive compound containing an effective amount of ebaf and a pharmaceutically acceptable carrier. A diagnostic kit for timing contraception containing reagents for screening a sample for the presence of ebaf. A method of treating endometrial irregularities by down-regulating the expression of ebaf.Type: ApplicationFiled: April 27, 2007Publication date: August 21, 2008Applicant: University of South FloridaInventors: Siamak Tabibzadeh, Ravi Kothapalli
-
Publication number: 20070172870Abstract: A method for the early diagnosing of selected adenccarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.Type: ApplicationFiled: January 17, 2007Publication date: July 26, 2007Applicant: UNIVERSITY OF SOUTH FLORIDAInventors: Siamak Tabibzadeh, Ravi Kothapalli
-
Patent number: 7211644Abstract: Methods and reagents for the diagnosis of female infertility, prognostic indicators for female infertility, compounds for the treatment of female infertility, compounds and methods for contraception. Methods and compounds are based on the levels of ebaf in endometrial tissue. Methods for diagnosing endometrial receptivity and bleeding function by screening a biological sample such as an endometrial tissue sample, or bodily fluid for the presence of ebaf. A contraceptive compound containing an effective amount of ebaf and a pharmaceutically acceptable carrier. A diagnostic kit for timing contraception containing reagents for screening a sample for the presence of ebaf. A method of treating endometrial irregularities by down-regulating the expression of ebaf.Type: GrantFiled: April 29, 1999Date of Patent: May 1, 2007Assignee: University of South FloridaInventor: Siamak Tabibzadeh
-
Publication number: 20060099576Abstract: The present invention provides a method for determining whether a subject has a pre-neoplastic or neoplastic lesion in transitional epithelial cells. The present invention further provides a method for assessing the efficacy of therapy to treat a pre-neoplastic or neoplastic lesion in transitional epithelial cells in a subject who has undergone or is undergoing treatment for a pre-neoplastic or neoplastic lesion in transitional epithelial cells. Finally, the present invention provides a method for assessing the prognosis of a subject who has a pre-neoplastic or neoplastic lesion in transitional epithelial cells.Type: ApplicationFiled: December 11, 2001Publication date: May 11, 2006Inventor: Siamak Tabibzadeh
-
Patent number: 6747004Abstract: The present invention provides a method of inducing growth or enhancing survival of nervous tissue comprising contacting the nervous tissue with an amount of ebaf effective to induce the growth or enhance the survival of the nervous tissue. The present invention also provides a method for treating a subject having damaged or degenerated nervous tissue comprising administering to the subject an amount of ebaf effective to treat the damaged or degenerated nervous tissue in the subject. The present invention further provides a method for treating a neurodegenerative disease in a subject comprising administering an amount of ebaf effective to treat the neurodegenerative disease. The present invention still further provides a method for preventing the onset or reducing the severity of damaged or degenerated nervous tissue in a subject comprising administering an amount of ebaf effective to prevent the onset or reduce the severity of the damaged or degenerated nervous tissue.Type: GrantFiled: April 28, 2000Date of Patent: June 8, 2004Assignee: North Shore - Long Island Jewish Research InstituteInventor: Siamak Tabibzadeh
-
Patent number: 6683156Abstract: A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the, bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.Type: GrantFiled: March 16, 2000Date of Patent: January 27, 2004Assignee: University of South FloridaInventor: Siamak Tabibzadeh
-
Patent number: 6649588Abstract: The present invention provides a method for inhibiting activity of TGF-&bgr;, comprising contacting tissue expressing TGF-&bgr; with an amount of ebaf or an ebaf analogue. The present invention further provides a method for treating a condition associated with overactivity of TGF-&bgr;, particularly fibrosis, a defect in cell proliferation, or a coagulation defect. The present invention also provides a method for inhibiting activity of TGF-&bgr;, comprising contacting tissue expressing TGF-&bgr; with a modulator of ebaf expression, or a modulator of expression of an ebaf analogue. The present invention is further directed to a method for treating fibrosis in a subject in need of treatment, comprising administering to the subject an amount of ebaf or an ebaf analogue effective to treat the fibrosis.Type: GrantFiled: October 5, 2000Date of Patent: November 18, 2003Assignee: North Shore - Long Island Jewish Research InstituteInventors: Siamak Tabibzadeh, James M. Mason
-
Publication number: 20030032047Abstract: A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.Type: ApplicationFiled: July 26, 2002Publication date: February 13, 2003Inventor: Siamak Tabibzadeh
-
Patent number: 6294662Abstract: A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.Type: GrantFiled: June 29, 1999Date of Patent: September 25, 2001Assignee: University of South FloridaInventor: Siamak Tabibzadeh
-
Patent number: 5916751Abstract: A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene, the gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.Type: GrantFiled: August 27, 1997Date of Patent: June 29, 1999Assignee: University of South FloridaInventors: Siamak Tabibzadeh, Ravi Kothapalli
-
Patent number: RE40937Abstract: A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.Type: GrantFiled: May 9, 2007Date of Patent: October 13, 2009Assignee: University of South FloridaInventors: Siamak Tabibzadeh, Ravi Kothapalli
-
Patent number: RE41007Abstract: A method for the early diagnosing of selected adenocarcinomas in a human comprising the steps of removing a bodily sample from the human, and assaying the bodily sample for elevated expression of a specific gene. The gene being assayed for in the, bodily sample is the TGFB-4 gene (hereinafter referred to as the endometrial bleeding associated factor (ebaf) gene. The bodily sample can be tissue from a specific organ in the body, or a blood sample. Increased levels of ebaf in the sample relative to basal levels may be indicative of a mucinous adenocarcinoma of the colon or ovaries, or an adenocarcinoma of the testis.Type: GrantFiled: May 9, 2007Date of Patent: November 24, 2009Assignee: University of South FloridaInventors: Siamak Tabibzadeh, Ravi Kothapalli